Stephen O’Hara, CEO of OptiBiotix, commented: “We are extremely pleased with the very high level of interest from both national and multinational companies interested in selling our products. This has
Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce this non-exclusive license agreement with Nutrilinea for the production and commercialisation of products containing OptiBiotix’s LP(LDL) (R) strain for
OptiBiotix Health’s Stephen O’Hara discusses the listing of SkinBiotherapeutics PLC onto the AIM market, what this means for shareholders and how it fits in with OptiBiotix Health’s overall strategy in this exclusive interview with DirectorsTalk
Stephen O’Hara, CEO of OptiBiotix LON:OPTI, commented: “OptiBiotix has made significant progress in the last year in building the infrastructure and team to support the transition from a technology company,
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the listing of SkinBiotheraputics (LON:SBTX). Stephen explains the rationale behind the launch, what this could mean for OptiBiotix investors,
SkinBioTherapeutics PLC (LON:SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM at 8:00am yesterday under the ticker
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, will announce its final results for the year ended 30
DirectorsTalk caught up with Optibiotix Health Plc (LON:OPTI) CEO Stephen OHara to comment on today’s news that sugar limits for everyday foods such as biscuits, chocolate bars and cereals have
Research presented by microbiologist Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI), at the Microbiome R&D and Business Collaboration Congress: Asia in Hong Kong on the 1-2 March 2017 demonstrated that
OptiBiotix Health’s Stephen O’Hara discusses their European manufacturing, supply and profit sharing agreement with Sacco and more agreements in the pipeline in this exclusive interniew with DirectorsTalk
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
